Parkinsons Disease Market Insights, Epidemiology and Market Forecast - 2028

Parkinsons Disease Market Insights, Epidemiology and Market Forecast - 2028

  • Pages: 120
  • Geography: 7MM (US, EU5, & Japan)
  • Delivery Timeline: 24 hours
  • Publication: Jul, 2019
  • SKU: DIMI0022A
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Parkinson's Disease Market Size | Parkinson's Disease Market Research Report 

DelveInsights ‘Parkinson's disease Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Parkinson's disease in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Parkinson's disease from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2028

Parkinson's disease - Disease Understanding and Treatment Algorithm

The DelveInsight Parkinson's disease market report gives a thorough understanding of the Parkinson's disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides Parkinson's disease treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Parkinson's disease

The Parkinson's disease epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Parkinson's diseaseTotal Diagnosed Prevalence of Parkinson's disease, Gender-specific Diagnosed Prevalence of Parkinson's diseaseAge-specific Diagnosed Prevalence of Parkinson's disease, and Stage-specific Prevalence of Parkinson's disease) scenario of Parkinson's disease in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight, the total number of diagnosed prevalent population of Parkinson's disease was found to be 1,373,639in the year 2017.

Parkinson's disease Drug Chapters

This segment of the Parkinson's disease report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.          

There are currently no disease-modifying drugs for PD, but the treatments that are used can offer significant symptomatic relief of the motor symptoms. They offer little clinical benefit in terms of the nonmotor manifestations of PD. It is usual practice to delay the initiation of treatment until the patients symptoms become troubling, to reduce the impact of adverse effects. The present treatment options include medicationsurgerycomplementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that includes Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists, MAO B inhibitors, Catechol O-methyltransferase (COMT) inhibitors, Anticholinergics, and Amantadine.

The drug to be used at the beginning of treatment of PD is either levodopa or a dopamine agonist. L-Dopa is a natural precursor of dopamine which is transformed in the brain into dopamine. It is the most effective available drug, although, after long-term use, complications can occur including motor fluctuations (an ‘on–off’ effect) and dyskinesias (abnormal involuntary movements), especially if high doses are taken over many years. In March 2017, the US food and drug administration (FDA) approved safinamide as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing “off” episodes.

Apart from the pharmacological therapies few companies are working in the development of gene and stem cell therapy, which can provide a cure to the disease.

Parkinson's disease Market Outlook

The Parkinson's disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Parkinson's disease in 7MM was found to be USD 1837.90 million in 2017 and is expected to increase at a CAGR of XX% from 2017-2028.

Parkinson's disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Parkinson's disease Report Insights

  •  Parkinson's disease Patient Population
  •  Parkinson's disease Therapeutic Approaches
  •  Parkinson's disease Pipeline Analysis
  •  Parkinson's disease Market Size and Parkinson's disease market trends
  •  Parkinson's disease Market Opportunities
  •  Impact of upcoming Therapies on Parkinson's disease 

Parkinson's disease Report Key Strengths

  • Parkinson's disease 10 Year Forecast
  • Parkinson's disease 7MM Coverage
  • Parkinson's disease Epidemiology Segmentation
  • Parkinson's disease Drugs Uptake
  • Highly Analyzed Parkinson's disease Market
  • Parkinson's disease Key Cross Competition

Parkinson's disease Report Assessment

  • Parkinson's disease Current Treatment Practices
  • Parkinson's disease Unmet Needs
  • Parkinson's disease Detailed Pipeline Product Profiles
  • Parkinson's disease Market Attractiveness
  • Parkinson's disease Market Drivers and Parkinson's disease Market Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Parkinson's disease market
  •  Organize sales and marketing efforts by identifying the best opportunities for Parkinson's disease market
  •  To understand the future market competition in the Parkinson's disease market

Report Introduction

Parkinson’s DiseaseMarket Overview at a Glance

Market Share Distribution of Parkinson’s Diseasein 2017

Market Share Distribution of Parkinson’s Diseasein 2028

Disease Background and Overview: %Disease%

Introduction

Symptoms

Etiology

Risk Factors

Pathophysiology

Diagnosis

Treatment

Epidemiology and Patient Population

Key Findings

Total Prevalent/ Incident Patient Population of Parkinson’s Diseasein 7MM

Total Prevalent  Patient Population of Parkinson’s Diseasein 7MM – By Countries

Epidemiology of Parkinson’s Diseaseby Countries

United States

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the Parkinson’s Disease*Indication Specific

Sex- Specific Cases of the %Disease%*Indication Specific

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

EU5

Assumptions and Rationale

Germany

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

France

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

Italy

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

Spain

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

United Kingdom

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

Japan

Assumptions and Rationale

Prevalent/Incident Cases of the %Disease%

Sub-Type Specific cases of the %Disease%*

Sex- Specific Cases of the %Disease%*

Diagnosed Cases of the %Disease%

Treatable Cases of the %Disease%

Current Treatment & Medical practices

Treatment Algorithm

Treatment Guidelines

Unmet Needs of the %Disease%

Marketed Therapies

Drug A: Company 1

Drug Description

Mechanism of Action

Regulatory Milestones

Advantages & Disadvantages

Product Profile

Drug B: Company 2

Drug Description

Mechanism of Action

Regulatory Milestones

Advantages & Disadvantages

Product Profile

Pipeline Therapies – At a glance

Key Cross Competition

Emerging Therapies for %Disease%

Drug C: Company 3

Drug Description

Clinical Trials Details

Safety and Efficacy Profile

Advantages & Disadvantages 

Pipeline Development Activities

Product Profile

Drug D: Company 4

Drug Description

Clinical Trials Details

Safety and Efficacy Profile

Advantages & Disadvantages 

Pipeline Development Activities

Product Profile

%Disease%: 7MM Market Analysis

7MM Market Size of %Disease%

7MM Percentage Share of drugs marketed for %Disease%

7MM Market Sales of Parkinson’s Diseaseby Products

%Disease%: Country-Wise Market Analysis

United States

Market Size of Parkinson’s Diseasein United States

Percentage Share of drugs marketed for Parkinson’s Diseasein United States

Market Sales of Parkinson’s Diseaseby Products in United States

Analysis of Upcoming Therapies and their Impact on the Market

EU-5

Germany

Market Size of Parkinson’s Diseasein Germany

Percentage Share of drugs marketed for Parkinson’s Diseasein Germany

Market Sales of Parkinson’s Diseaseby Products in Germany

Analysis of Upcoming Therapies and their Impact on the Market

France

Market Size of Parkinson’s Diseasein France

Percentage Share of drugs marketed for Parkinson’s Diseasein France

Market Sales of Parkinson’s Diseaseby Products in France

Analysis of Upcoming Therapies and their Impact on the Market

Italy

Market Size of Parkinson’s Diseasein Italy

Percentage Share of drugs marketed for Parkinson’s Diseasein Italy

Market Sales of Parkinson’s Diseaseby Products in Italy

Analysis of Upcoming Therapies and their Impact on the Market

Spain

Market Size of Parkinson’s Diseasein Spain

Percentage Share of drugs marketed for Parkinson’s Diseasein Spain

Market Sales of Parkinson’s Diseaseby Products in Spain

Analysis of Upcoming Therapies and their Impact on the Market

United Kingdom

Market Size of Parkinson’s Diseasein United Kingdom

Percentage Share of drugs marketed for Parkinson’s Diseasein United Kingdom

Market Sales of Parkinson’s Diseaseby Products in United Kingdom

Analysis of Upcoming Therapies and their Impact on the Market

Japan

Market Size of Parkinson’s Diseasein Japan

Percentage Share of drugs marketed for Parkinson’s Diseasein Japan

Market Sales of Parkinson’s Diseaseby Products in Japan

Analysis of Upcoming Therapies and their Impact on the Market

Market Drivers

Market Barriers

Appendix

Report Methodology

Sources

DelveInsight Capabilities

Disclaimer

About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 63: Japan-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Figure 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Figure 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 54: Italy-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 57: Spain-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Figure 60:UK-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Parkinson’s Disease in USD MM (2017-2028)

Figure 63: Japan-Market Share Parkinson’s Disease by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Parkinson’s Disease by Therapies in USD MM (2017-2028)

Table 1: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM

Table 2: Total Prevalent/Incident Cases of the Parkinson’s Diseasein 7MM by Countries

Table 3: Prevalent/Incident Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 4: Sub-Type Specific cases of the Parkinson’s Diseasein United States (2017-2028)

Table 5: Sex- Specific Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 6: Diagnosed Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 7: Treatable Cases of the Parkinson’s Diseasein United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 10: Sex- Specific Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 11: Diagnosed Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 12: Treatable Cases of the Parkinson’s Diseasein Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Parkinson’s Diseasein France (2017-2028)

Table 14: Sub-Type Specific cases of the Parkinson’s Diseasein France (2017-2028)

Table 15: Sex- Specific Cases of the Parkinson’s Diseasein France (2017-2028)

Table 16: Diagnosed Cases of the Parkinson’s Diseasein France (2017-2028)

Table 17: Treatable Cases of the Parkinson’s Diseasein France (2017-2028)

Table 18: Prevalent/Incident Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 20: Sex- Specific Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 21: Diagnosed Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 22: Treatable Cases of the Parkinson’s Diseasein Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 25: Sex- Specific Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 26: Diagnosed Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 27: Treatable Cases of the Parkinson’s Diseasein Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 29: Sub-Type Specific cases of the Parkinson’s Diseasein UK (2017-2028)

Table 30: Sex- Specific Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 31: Diagnosed Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 32: Treatable Cases of the Parkinson’s Diseasein UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 35: Sex- Specific Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 36: Diagnosed Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 37: Treatable Cases of the Parkinson’s Diseasein Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 42:7MM- Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 45: United States-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 48: Germany-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 51: France-Market Share Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Parkinson’s Diseaseby Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Parkinson’s Diseasein USD MM (2017-2028)

Table 54: Italy-Market Share Parkinson&rs